Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics Inc (BNGO) delivers cutting-edge optical genome mapping solutions for advanced genomic research. This news hub provides investors and researchers with essential updates on the company's innovations in structural variation analysis.
Access official press releases, financial disclosures, and technology developments in one centralized location. Track updates spanning product launches, clinical study collaborations, and peer-reviewed research validations of Bionano's OGM platform. Our curated collection ensures timely access to material developments impacting the genome analysis sector.
Key focus areas include regulatory milestones, partnership announcements, and scientific advancements demonstrating Bionano's leadership in next-generation cytogenetics. All content maintains strict factual accuracy required for informed investment decisions and research applications.
Bookmark this page for streamlined monitoring of Bionano's progress in transforming genomic medicine through high-resolution genome analysis tools. Verify critical updates directly from primary sources with our comprehensive news aggregation.
Bionano Genomics (NASDAQ:BNGO) announced a significant peer-reviewed publication demonstrating the effectiveness of their optical genome mapping (OGM) technology in detecting oncogenic structural variants in infant and toddler T-cell acute lymphoblastic leukemia (T-ALL).
The study, conducted across multiple French pediatric centers, analyzed 27 T-ALL cases in children under 3 years. Key findings include: 33% of cases carried previously uncharacterized NKX2 gene rearrangements, distinct genomic profiles compared to older children, and a 75.4% five-year overall survival rate. The research demonstrated OGM's ability to identify prognostic subgroups and detect complex genetic rearrangements in a single workflow, potentially improving disease classification and management.
Bionano Genomics (Nasdaq: BNGO) announced that CEO Erik Holmlin, PhD, will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025. The presentation is scheduled for 3:00 p.m. to 3:25 p.m. ET.
Investors can access the presentation through a webcast, and a replay will be available on the company's investor relations website for at least 30 days following the event.
Bionano Genomics (NASDAQ: BNGO) has announced significant upgrades to its software platforms VIA™ 7.2 and Solve™ 3.8.3, along with enhancements to its Stratys™ Compute server. The updates focus on improving the analysis of optical genome mapping (OGM), microarray, and NGS data.
Key improvements include AI-powered workflow transformation for constitutional genetic disorders, an 18% expansion of the structural variants control database, and the ability to double the number of cancer samples analyzed per week. The software releases will initially be available to 20 early access users, with broad commercial release expected in Q4 2025.
The upgrades introduce significance associated with phenotype (SAP) scoring for OGM data and enhance the system's ability to learn from historical lab results, improving interpretation speed and accuracy.
Bionano Genomics (Nasdaq: BNGO) has scheduled its second quarter 2025 financial results conference call and webcast for August 14, 2025, at 4:30 p.m. Eastern Time. The company will present its Q2 2025 financial performance and provide updates on recent corporate developments.
Investors and interested parties can access the live webcast through the company's investor relations website. A replay of the presentation will be available for at least 30 days after the event on Bionano's IR website at ir.bionano.com.
Bionano Genomics (NASDAQ: BNGO) showcased significant momentum for its Optical Genome Mapping (OGM) technology at the 2025 European Cytogenomics Association (ECA) conference in Leuven, Belgium. The event featured 16 scientific studies from seven countries, marking an increase from 14 studies in 2023 and 9 in 2021.
The conference included two hands-on workshops focused on VIA™, Bionano's analytical suite for structural variation analysis, led by key opinion leaders from Belgium and France. Research presentations covered applications in multiple myeloma, non-Hodgkin lymphoma, and various genetic disorders, demonstrating OGM's growing adoption in clinical cytogenomics research across Europe and the Middle East.
Bionano Genomics (NASDAQ: BNGO) has scheduled its first quarter 2025 financial results conference call and webcast for Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time. The company will present its Q1 2025 financial performance and provide updates on recent corporate developments. Investors and interested parties can access the live webcast through the company's investor relations website, where a replay will be available for at least 30 days following the presentation.
Bionano Genomics (BNGO) has published a peer-reviewed study in Genome Research demonstrating the effectiveness of optical genome mapping (OGM) in detecting large repeat expansions linked to genetic disorders. The research, conducted at Radboud University Medical Center, evaluated 85 subjects with known pathogenic expansions in three genes associated with myotonic dystrophy and CANVAS syndrome.
The study revealed key findings:
- 98.8% detection accuracy (84 out of 85 cases)
- Accurate measurement of repeat sizes, even exceeding 7,000 units
- Detection of somatic instability in 36 out of 85 samples
- Single comprehensive assay capability across multiple loci
The research suggests OGM could provide a more cost-effective and efficient alternative to traditional methods like PCR, Southern blotting, and next-generation sequencing for analyzing repeat expansions in genetic disorders.
Bionano Genomics (BNGO) has announced a breakthrough study published in The Journal of Molecular Diagnostics regarding the analysis of multiple myeloma (MM) using optical genome mapping (OGM). The research, conducted at Lille University Hospital, France, demonstrates an innovative method that reduces the required number of CD138-positive cells by half for MM analysis.
The study revealed that mixing CD138-positive and negative cells in a 1:1 ratio is sufficient for OGM analysis, requiring only 0.5 million CD138-positive cells instead of the typical 1 million. The method achieved 93% concordance with traditional FISH testing while detecting 22 additional genetic variants. This advancement streamlines laboratory workflows by consolidating multiple tests into a single comprehensive approach and improves prognostic risk evaluation through more detailed genomic profiling.
FAQ
What is the current stock price of Bionano Genomics (BNGO)?
What is the market cap of Bionano Genomics (BNGO)?
